echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 3. In 75 days, a pharmaceutical company listed on the capital-intensive layout of biomedicine "asset transfer"?

    3. In 75 days, a pharmaceutical company listed on the capital-intensive layout of biomedicine "asset transfer"?

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the first half of this year, biopharmaceutical investors are very busy!
    " Monday busy: Fudan Zhangjiang hit new, photodynamic platform in the global PK of the scarce target, previously only listed in Hong Kong stocks, and finally back to the board! Tuesday continues: Shenzhou cell hit new, 21 innovative drugs in research, pipeline rich buy! "
    turn 618 is coming, first take a two-day break to leave some money for his wife to empty the shopping cart ... June 16, Gan Li Pharmaceuticals hit a new, buy not buy? "The first Chinese company to master the technology of industrial production of recombinant insulin analogues, the Changxiu yu used by our father was Gan Li's first brand product." Stable performance, differentiated portfolios must be bought.
    618 fightued until 2 a.m., 619 continues. "Fast, Fudan Zhangjiang open up 340%, into the account XXXXXXX seven-digit, 2020 is too beautiful, who want to restart!" At the end of the month, there is Kangji Medical listed in Hong Kong stocks, China's largest minimally invasive surgical instruments, screening will be calculated ...
    . The story points to the end and begins to get to the point. The above scenario is not pure fiction, but the biopharmaceutical industry is really experiencing such an unprecedented "asset movement." It can be said that the "gold rush" era of biomedicine in 2020 officially opened!
    01 phenomenon one: IPO was ignited, 3.75 days a pharmaceutical company listed
    a weekly biopharmaceutical company listed, even more in July, every 3.75 days there is one, miss Junshi biological, and three life sons. Biopharmaceutical plate high-quality target, more and more. In the past, the "new" of unprofitable biopharmaceuticals could be said to have made their way to NASDAQ, but now, when asked where they want to go public, the bosses' answers have changed! "No more nasdaq! Hong Kong Stock Exchange, Science and Technology Board is also a good choice!
    Zhitong Finance recently reported that re-Ding Pharma, which is now listed on NASDAQ, is preparing to return to Hong Kong for its second listing, with JPMorgan Chase and Citigroup in charge of the project. If all goes well, Reding Pharma is expected to list as soon as the fourth quarter of this year, becoming the second second-largest biopharmaceutical stock listed in Hong Kong after Baiji Shenzhou. Similarly, First Sound Pharmaceuticals is also a recent high-heat pharmaceutical company to go to Hong Kong to list, and re-Ding Pharmaceuticals, unlike Reding Pharmaceuticals, has been delisted on the Nyse in 2014.
    While there is little return, spin-off listings may be a trend. In the first half of 2020, seven pharmaceutical companies announced that they would spin off their subsidiaries to GEM or the company board. Among them, including Changchun High-tech, Hualan Bio, Liaoning Chengda will be its vaccine business spin-off, Tianshili will be committed to drug research and development of The Skyforce biological spin-off, Collon Pharmaceuticals will be committed to large infusion, antibiotics and drug research and development of the Chuanning biological spin-off.
    also, "A-H" is also a major source of contribution for high-quality targets.
    years ago, the drug Mingkang to "one-down three" to complete the "A-H" listing layout, has now become a textbook case is imitated, "A-H" dual financing platform is being included in the boss's consideration, in which A more choice lies in the board.
    also has a small number of first A after H, hepri is the latter, the company is the heparin industry chain of large factories, recently through the Hong Kong Stock Exchange hearing, to raise 2.34 billion Hong Kong dollars into marketing, production, innovative drugs. There may be more cases from H to A, especially for unprofitable biopharmaceutical companies, because the HKEx first implemented the New Deal and then the board. In the case of Consino, in Hong Kong stocks is a scarcity target, and so is the case with the CKeboard. There are junshi creatures, although in the new three board listing, but in view of the liquidity considerations, or belong to the first H after A situation.
    has been a while since the opening of the Hong Kong Stock Exchange's New Deal and the Board of Science and Technology, and the market performance has been evident to all. Therefore, there is still a situation of A-H almost simultaneously carried out, such as Bai Oae, just listed in Cotron Board in February, in June on the Hong Kong Stock Exchange submitted a listing application. The company's current listed products are the first Adamu monoanti-biosimilar drugs, the prospects are quite broad, however, there are many competitors, similar original research drugs have 4, domestic has been listed in the sea zheng pharmaceutical industry, in the 3rd stage or NDA stage has 6 enterprises, Junshi is one of the strong rivals. So, for a player like Aotai, the main thing is to grab time and speed.
    summary, when the re-ding choose from the NASDAQ back to the Hong Kong Stock Exchange, when Kangsino, Junshi people chose "A-H", Bai Oai chose to "two-pronged", the IPO market was ignited behind, is a real sense of innovative drugs, innovative medical competition for the beginning.
    in this battle, policy has become the support of capital, and capital has become the hands of the bio-pharmaceutical upset "race weapon", under the dual role, accelerate the reconfiguration of resources in the biopharmaceutical industry.
    02 phenomenon 2: nearly 90% of the 100 institutions declined, the trend of growth are added to the number of health care
    . The IPO goes back to the more closed primary market, the cradle of the growth of biopharmaceutical upstarts. Because of the particularity of the new drug, the biopharmaceutical circuit is not only a group of determined scientists, but also a group of long-term vision and highly resilient investors.
    from the actions of these investors, you can get a glimpse of this year's biopharmaceutical primary market some of the key. According to investment data of 100 investment institutions compiled by Sky Eye, the number of investments by H1,81 investment institutions in 2020 was lower than in the same period, of which 20 were down by more than 70% Year-on-Year, 4 were flat with history, and only 12 investment institutions achieved counter-trend growth.
    further combed these 12 institutions, including health care investment-focused institutions (defined as the top two in the historical investment of healthcare investment) accounted for more than half, involving Sequoia Capital China, Ida Capital, Huagai Capital, Yuanyu Holdings, Sdao Capital and other 7 well-known institutions. Most of the seven institutions have, as always, maintained investment in health care, compared with Yuanyu Holdings, which invested more in the first half of this year than in the whole of last year. Participated in The E-wheel of Changfeng Pharmaceuticals, the A-wheel of CreeGene, the B-wheel of the drug Ming Juno, the first 2 are Suzhou Company, and the drug Ming Juno also has CAR-T factory in Suzhou BIOBAY. Yuanyu Holdings, formerly known as Suzhou Venture Capital, is an important supporting institution for Suzhou BIOBAY.
    five other non-focused healthcare investment institutions that grew, and two of them added health care in the first half of this year, making it a focus area of investment during the period. Of these, 4 of SIG's 13 investments in Asia went to healthcare, and three of Fosun's five investments went to healthcare, including Newforth's Round A, which is the country's first ophthalmic gene drug developer, along with Sequoia Capital and Northern Lights Ventures.
    , it seems that the growing institutions have more or less added to the health care sector. On the other hand, among the institutions that have slowed down overall, the top investment institutions that focus on healthcare investments (defined as the number one healthcare investment in history and the significant advantage over other areas) remain busy.
    Obo Capital is the head of medical investment, in 2020 H1 16 investments, the amount equivalent to "1 high-rise plus 0.75 Qiming Ventures", an increase of 33.33 percent over the same period last year, most of which are cornerstone investments, including Kangfang Bio, Peijia Medical and so on. The agency's first-half trading was focused on June, with six investments, including four cornerstone investors in Kangji Medical, Stone Burning Medicine and Oconvision, including a $500 million B-round financing. Other well-known biopharmaceutical investment institutions have largely maintained their 2019 levels, such as Qiming Ventures (8), Lilly Asia (7), Hongyu Capital (6), Vito capital (4) and others.
    may also be reducing investment in other areas, which is falling overall, but investment in health care is still being added. This year's passive high-profile high-profile capital in the biopharmaceutical capital market is one of the most prominent examples, the number of H1 investments in 2020 is 10 (excluding GaoGao Ventures), which has exceeded the whole of 2019. The agency completed four investments in June, including cornerstone investments in Heigia Healthcare and Conky Healthcare, as well as The C and Jiaandi B rounds of Genting's New Yew. Further forward because of the Kelelion, Kelly Tai ding increase, Hualan bio-vaccine strategic investment, become a biopharmaceutical capital market "walking flow package", the status of envy of others.
    03 phenomenon three: the average increase of the secondary market 25%, Hengrui, Meirui, pharmaceutical Ming and other market value upgrade
    for ordinary investors, the primary market is usually difficult to participate in, the secondary market is more closely related. In 2020, biopharmaceutical investors are going through an unprecedentedly good time, no longer just Hang Rui's good times. "In the first half of this year, half of the chances have risen by more than 20%."
    the outbreak, more than 20% of the treatment is limited to biomedicine, consumption second. Like tourism, film and television entertainment prayer is not bankrupt is the biggest luxury, last year's long-term favored computer, electronics, 5G and other sub-sectors of the overall performance is also very dismal. According to choice data, as of June 22, 2020, the cumulative increase in A-shares, the cumulative increase in the biopharmaceutical sector of the median increase of 23.11%, food and beverage, electronics, computers, communications 16.39%, 6.43%, 4.24% and -0.66%.
    specific to the most bright-eyed company, but also the flower-falling biopharmaceutical industry, the highest increase of 17 times, is from Beijing's Wantai biological. The company's main products are enzyme-linked immunodiagnostic reagents, colloidal gold rapid diagnostic reagents and so on. It is worth noting that Wantai Bio was listed on the Shanghai Stock Exchange on April 29 this year, and it has won 26 ups and downs as soon as it is listed.
    not just Wantai Bio, a number of 2020 listed in vitro diagnostic enterprises were snapped up, occupying the rise of TOP5 three seats. On May 12, the Shenzhen Stock Exchange listed IVD head enterprises, new industrial biology has also reaped a 424% increase, the company's main products for a series of fully automatic chemical luminescence immunoassay instruments and supporting reagents, early by Sequoia Capital favor edirated and has been invested. Ten years away, Sequoia also gets a book return of more than 70 times. Another POCT instant diagnostic reagent manufacturer, Oriental Bio, also rose more than five times.
    also an important feature of the first half of the year is that many biopharmaceutical companies continue to rise to record highs, achieving a market value upgrade.
    , for example, HengRui recently hit a market capitalisation of $500 billion. Meirui Medical Refresh officially entered 300 billion files, an increase of about 65%, as of the date of writing market value of more than 360 billion yuan; Also in the billion-dollar market value range are Aer Ophthalmology (51%), Changchun High-tech (up 79%), Zhifei Bio (98%), Yunnan White Medicine (5%), Kantai Bio (77%), most of which are entering this year.
    04 Phenomenon IV: Multinational MNC has started to carry out innovative investment transactions in China
    in the past, multinational pharmaceutical companies through their investment institutions to participate in the investment in local biopharmaceuticals, has been a rare state. Of course, Lilly Asia is a particular presence, having started with Lilly Pharmaceuticals' venture capital arm in 2008 and has been involved in investments in United Pharmaceuticals (an ANDA regular) and Microcore Bio (innovative drug upstart). Prior to independence in 2011, he was also involved in investments in Beida Pharmaceuticals and Berry Pharmaceuticals, both of which are now listed and have performed well in the capital markets.
    2014, Lilly Pharmaceuticals became one of the most prominent MNCs in the Chinese market for plus-size in response to the "patent cliff" crisis. Consistent with many MNc, Lilly is also investing heavily in building factories and research and development centers. More forward-looking, however, Lilly Pharmaceuticals has begun to extend its capital reach to leading domestic research and development companies in the form of venture capital funds.
    most of today's HONG Kong Stock Exchange biopharmaceutical upstarts have received Lilly investments, such as the domestic PD-1 four-dragon Xinda Bio, which was targeted by Lilly in 2013, and Concino, who stood out in the development of the new crown vaccine, received Lilly's investment shortly after its inception. This year's listing of Pejia Medical, stone-burning medicine, etc. have Lilly's figure, compared with Lilly Pharmaceuticals itself in China, Lilly Asia Fund's position is undoubtedly better.
    it is worth noting that, in addition to the Active Domestic Investment Circle Lilly Asia Fund non-stop addition, this year the domestic biopharmaceutical investment market will usher in two MNc - Sanofi and Bollinger Ingham. On June 10,
    , Sanofi announced a strategic investment in the Kaihui Fund, and the company's President of China, He En-yin, said the partnership will leverage the advantages of Kaihui's selection and investment companies to help Sanofi connect with Chinese healthcare start-ups. On July 2,
    , Bollinger Ingerheim announced the launch of China's first external innovation cooperation center in Shanghai, where the director, Dr. Zhang Yiyi, believes that the whole of Asia is becoming a hot spot for biomedical research, with the strength of Biopharmaceutical Innovation in China greatly enhanced, and Bollinger Ingerheim's goal is to be the partner of choice in the innovation ecosystem. Specific ally to the business level, is to discover new technology in biomedicine, through licensing transactions to introduce research and development pipelines, venture capital to hatch early projects.
    connection, this is not a simple separation of two things, but is a signal: more and more multinational pharmaceutical companies are beginning to recognize China's indigenous biopharmaceutical innovation!
    in the past, why didn't multinational drug companies invest in local drug companies in China, but did they do it with their sleeves? Because in their perception, Chinese drug companies are doing only generics, Me-too, Me-better and other low-threshold things, most of them, simply can not help their future competition in the field of new drugs. Now, that perception is changing!
    look at the world's biopharmaceutical venture capital institutions, such as Johnson and Johnson, Pfizer, BMS, Novartis, Bayer and other well-known MNc have, but only in foreign regions to participate in venture capital, to witness the performance of Lilly Asia, from Sanofi, Bollinger Ingehan, will eventually usher in more venture capital into!
    05 Logic V: New drug NDA, IND explosion!
    the frenzy of the secondary market, the outbreak of IPO, the tenacity of the primary market, the change of foreign investment cognition, is not accidental, but sooner or later. The logic behind the official opening in 2020 is that there has been varying degrees of growth, whether it has been approved for listing, whether it is on the market, or for a clinical trial of a new drug, both of which can be described as an "explosion".
    the approval of new drugs to market is the most direct example. In 2020, an outbreak broke out without affecting the progress of drug approvals. In the first half of 2020, NMPA approved 27 new drugs, including 17 imported drugs and 10 domestically produced drugs, according to CDE. (This statistic is mainly in category 1 and.)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.